Tüdőrák: vizsgálatok itt: Kína

In Kína 1144 Also abroad 2746

1144 trials · From ClinicalTrials.gov, checked 2026. november 15.. Ask the study team whether a trial fits you.

1. fázisCsak meghívásos
Evaluation of the I-phase Clinical Trial of 177Lu-HX02 Injection in Patients With Advanced Malignant Solid Tumors
Where
Wuhan
Életkor
18 év to 75 év
People
12
Run by
Hexin (Suzhou) Pharmaceutical Technology Co., Ltd
See details and how to joinNCT07920822
1/2. fázisTaking people
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
Where
Changsha, Harbin, Shanghai
Életkor
18 év and over
People
320 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT05789082 · EU 2023-507171-22-00
3. fázisTaking people
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Where
Beijing, Bengbu, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Nanchang, Nantong, Shanghai, Shantou, Wuhan
Életkor
18 év and over
People
600 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06793215
No phaseTaking people
Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy
Where
Beijing, Changsha, Changzhou, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Huzhou, Jiangmen, Jinan, Kaifeng, Lanzhou, Nanchang, Nanjing, Nantong, Ningbo, Shanghai, Shengyang, Shenzhen, Shijiazhuang, Taiyuan, Taizhou, Tianjin, Ürümqi, Wuhan, Wuxi, Xi'an, Yinchuan, Zhanjiang, Zhengzhou, Zunyi
Életkor
18 év and over
People
800
Run by
Hoffmann-La Roche
See details and how to joinNCT06862869
1. fázisNot yet taking people in Kína
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Where
Changsha
Életkor
18 év and over
People
540 worldwide
Run by
Pfizer
See details and how to joinNCT07090499 · EU 2025-521729-33-00
3. fázisTaking people
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Where
Beijing, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Nanchang, Nanjing, Nanning, Shanghai, Taizhou, Wuhan, Xi’an, Xuzhou, Zhengzhou
Életkor
18 év and over
People
680 worldwide
Run by
Pfizer
See details and how to joinNCT07144280 · EU 2025-521281-97-00
3. fázisTaking people
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
Where
Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Jinan, Jingzhou, Linhai, Nanchang, Shanghai, Shanghai Shi, Shantou, Shenyang, Shenzhen, Suzhou, Taiyuan, Wuhan, Xi'an, Xi’an, Zhengzhou
Életkor
18 év and over
People
850 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07361497 · EU 2025-523576-23-00
No phaseTaking people
Real-World Outcomes of Sevabertinib in HER2-Mutant Advanced NSCLC: A Bidirectional Cohort Study
Where
Qionghai
Életkor
18 év and over
People
16
Run by
Ruijin Hospital
See details and how to joinNCT07880353
1/2. fázisTaking people
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Where
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fujian, Guangdong, Hangzhou, Henan, Hubei, Nanchang, Shanghai, Shanxi, Shengyang, Tianjin
Életkor
18 év and over
People
952 worldwide
Run by
Genmab
See details and how to joinNCT05579366
3. fázisTaking people
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Where
Beijing, Changchun, Changsha, Changzhou, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Jinan, Linhai, Linyi, Liuzhou, Nanchang, Nanjing, Shanghai, Tianjin, Ürümqi, Wuhan, Xi’an, Xiangyang, Yichang, Zhanjiang, Zhuzhou
Életkor
18 év and over
People
1264 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06119581 · EU 2023-503412-33-00
3. fázisNot yet taking people in Kína
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Where
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Linyi, Nanjing, Nanning, Shanghai, Taizhou, Wuhan, Xiamen
Életkor
18 év and over
People
444 worldwide
Run by
Bayer
See details and how to joinNCT06452277 · EU 2024-511319-91-00
1. fázisTaking people
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Where
Beijing, Guangzhou, Shanghai
Életkor
18 év and over
People
460 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06465069 · EU 2024-512927-36-00
3. fázisTaking people
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Where
Anyang, Beijing, Changchun, Changsha, Chengdu, Chongqing, Foshan, Guangzhou, Hangzhou, Harbin, Jinan, Linhai, Liuzhou, Luoyang, Nanning, Shanghai, Shantou, Shenzhen, Suzhou, Tianjin, Wuhan, Xi’an, Zhongshan
Életkor
18 év and over
People
700 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06890598 · EU 2024-512302-25-00
2. fázisTaking people
A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
Where
Beijing, Chongqing, Guangzhou, Shanghai, Xinxiang
Életkor
18 év and over
People
254 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07492680
2. fázisTaking people
Befotertinib Plus Chemotherapy With an MRD-guided Adaptive Strategy for Treatment Escalation and Response Optimization in EGFR-mutated NSCLC Patients
Where
Guangzhou
Életkor
18 év and over
People
124
Run by
Guangzhou University of Traditional Chinese Medicine
See details and how to joinNCT07709585
2. fázisNot yet taking people in Kína
Low-Dose Radiotherapy Plus Adebrelimab and Chemotherapy for Extensive-Stage Small Cell Lung Cancer
Where
Tianjin
Életkor
18 év to 75 év
People
25
Run by
Tianjin Medical University Cancer Institute and Hospital
See details and how to joinNCT07909863
No phaseTaking people
68Ga-labeled Cholecystokinin Receptor (CCK2R) Targeted Molecular Probes in Early Tumor Diagnosis
Where
Nanjing
Életkor
18 év to 75 év
People
20
Run by
Nanjing First Hospital, Nanjing Medical University
See details and how to joinNCT07914764
No phaseCsak meghívásos
Application of Generative Artificial Intelligence in Perioperative Personalized Rehabilitation for Older Adults With Lung Cancer
Where
Beijing
Életkor
65 év and over
People
150
Run by
Peking University Cancer Hospital & Institute
See details and how to joinNCT07915193
No phaseCsak meghívásos
Single-center Transformational Study on Feasibility and Efficacy of Respiratory Motion Management Using Novel Position Fixation Device for Lung Cancer Patients Undergoing Stereotactic Body Radiation Therapy(2023 No.358 Project)
Where
Tianjin
Életkor
18 év to 85 év
People
50
Run by
Tianjin Medical University Cancer Institute and Hospital
See details and how to joinNCT07916129
2. fázisTaking people
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Where
Baoding, Changchun, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Huizhou, Liuzhou, Shanghai, Tianjin, Wenzhou, Wuhan, Wuxi, Xi'an, Yantai
Életkor
18 év and over
People
520 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT05498428 · EU 2023-505065-91-00
3. fázisFut, nem toboroz
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
Where
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Nanchang, Neijiang, Shanghai, Shijiazhuang, Taizhou, Wuhan, Wuxi, Xiamen, Xiangyang, Xuzhou, Zhanjiang, Zhengzhou
Életkor
18 év and over
People
614 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06170788 · EU 2023-503376-24-00
2. fázisTaking people
A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
Where
Dongguan, Guangzhou, Jinan
Életkor
18 év and over
People
130 worldwide
Run by
Johnson & Johnson Enterprise Innovation Inc.
See details and how to joinNCT06667908 · EU 2024-518276-32-00
1/2. fázisTaking people
A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer
Where
Guangzhou, Harbin, Shanghai
Életkor
18 év and over
People
60 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07227025
2. fázisTaking people
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
Where
Beijing, Changchun, Nanjing, Shanghai, Tianjin, Zhangjiakou, Zhengzhou
Életkor
18 év and over
People
240 worldwide
Run by
Genmab
See details and how to joinNCT07288177 · EU 2025-522107-18-00
2. fázisTaking people
A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC
Where
Beijing, Chengdu, Cheng Du Shi, Guangzhou, Jinan, Shanghai, Tianjin
Életkor
18 év and over
People
68 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07586202